|Mr. James R. Sapirstein R.Ph., M.B.A.||CEO, Pres & Non-Independent Director||443.61k||N/A||1961|
|Dr. James E. Pennington||Chief Medical Officer||330k||N/A||1943|
|Mr. Martin Krusin||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Mr. Daniel H. Schneiderman||Chief Financial Officer||N/A||N/A||1978|
|Dr. Mathieu SchuÃ© Ph.D.||Head of Laboratory||N/A||N/A||N/A|
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of therapeutic proteins under development, including MS1819-SD, a yeast derived recombinant lipase for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase enzyme combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea, as well as AZX1103, a b-lactamase enzyme combination. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
AzurRx BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.